The impact of personalised therapies on respiratory medicine

European Respiratory Review

Volumn 22, Issue 127, 2013, Pages 72-74

  Elborn, J Stuart ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Cystic fibrosis; Personalised medicine; Potentiator therapy

Indexed keywords

ATALUREN; CHLORIDE CHANNEL AFFECTING AGENT; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; LUMACAFTOR; PLACEBO; UNCLASSIFIED DRUG; VX 661;

ABDOMINAL PAIN; CHANNEL GATING; CYSTIC FIBROSIS; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; GENE MUTATION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; PERSONALIZED MEDICINE; RESPIRATORY TRACT DISEASE; REVIEW; SPIROMETRY;

AMINOPHENOLS; CHLORIDES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; LUNG; MOLECULAR TARGETED THERAPY; MUTATION; PATIENT SELECTION; PHENOTYPE; PULMONARY MEDICINE; QUINOLONES; RESPIRATORY SYSTEM AGENTS; SWEAT; TREATMENT OUTCOME;

EID: 84874750063     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00008212     Document Type: Review

References (21)

1. Elborn JS. Personalised medicine for cystic fibrosis: treating the basic defect. Eur Respir Rev 2013; 22: 3-5.
2. Hall IP. Stratified medicine: drugs meet genetics. Eur Respir Rev 2013; 22: 53-57.
3. Derichs N. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators modulators in cystic fibrosis. Eur Respir Rev 2013; 22: 58-65.
4. Sermet-Gaudelus I. Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation. Eur Respir Rev 2013; 22: 66-71.
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
6. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
7. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820.
8. Pearson ER, Flechtner I, Njolstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006; 355: 467-477.
9. Ou SH, Bartlett CH, Mino-Kenudson M, et al. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012; 17: 1351-1375.
10. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13: 1011-1019.
11. Todd JL, Goldstein DB, Ge D, et al. The state of genome-wide association studies in pulmonary disease: a new perspective. Am J Respir Crit Care Med 2011; 184: 873-880.
12. Prefontaine D, Nadigel J, Chouiali F, et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol 2010; 125: 752-754.
13. Smith DE. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy 2010; 40: 200-208.
14. Ober C, Yao TC. The genetics of asthma and allergic disease: a 21st century perspective. Immunol Rev 2011; 242: 10-30.
15. Clancy JP, Jain M. Personalized medicine in cystic fibrosis: dawning of a new era. Am J Respir Crit Care Med 2012; 186: 593-597.
16. Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Nat Acad Sci USA 2011; 108: 18843-18848.
17. Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 2012; 142: 718-724.
18. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372: 719-727.
19. Sermet-Gaudelus I, Boeck KD, Casimir GJ, et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 2010; 182: 1262-1272.
20. Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012; 67: 12-18.
21. Pettit RS. Cystic fibrosis transmembrane conductance regulatormodifying medications: the future of cystic fibrosis treatment. Ann Pharmacother 2012; 46: 1065-1075.